SOHO 2023 | Treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
In this video, Marc Braunstein, MD, PhD, NYU Long Island School of Medicine, New York City, NY, shares some insights into treatment selection and sequencing in patients with relapsed, intolerant, or refractory multiple myeloma (MM), highlighting the importance of utilizing different therapy combinations to overcome resistance. Dr Braunstein addresses the evolving treatment landscape of this disease, which includes bispecific antibodies such as teclistamab and talquetamab, CELMoDs like iberdomide, and CAR-T cells. Dr Braunstein also discusses the patient, disease, and treatment variables which should be considered when identifying the optimal treatment sequence for a patient. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: Consultant (advisory board), Adaptive Biotechnologies: Consultant (advisory board)
ADC Therapeutics: Consultant (advisory board), American College of Physicians: MSKAP Question Writer, Bristol Myers Squibb: Consultant (advisory board), Janssen: Faculty bureau, Bristol Myers Squibb: Research funding, CTI Biopharma: Consultant (advisory board), Epizyme: Consultant (advisory board), Glaxosmithkline: Consultant (advisory board), Guidepoint: Consultant, Janssen: Consultant (advisory board), Janssen: Research funding, LAVA Therapeutics: Consultant (advisory board), Pfizer: Consultant (advisory board), Pfizer/ICON: Clinical independent reviewer, Sanofi: Consultant, Seagen: Consultant (advisory board)
